Cheratussin AC

Product NDC: 0603-1075
11-digit product format: 006031075
Labeler code: 0603
Product ID: 0603-1075_8b814721-ce39-46fa-96c8-5f2665c3c59c
Type: HUMAN OTC DRUG
Nonproprietary name: codeine phosphate and guaifenesin
Dosage form: LIQUID
Route: ORAL
Labeler: Par Pharmaceutical
Application: part341
Marketing category: OTC MONOGRAPH FINAL
Marketing start: 1996-09-01
Marketing end: 2020-03-31
Substance: CODEINE PHOSPHATE; GUAIFENESIN
Active strength: 10 mg/5mL; mg/5mL
DEA schedule: CV
NDC exclude flag: No
Listing certified through: 0000-00-00
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 4 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Source date
excluded product	product	0603-1075		D	Discontinued by firm	2026-10-12
excluded package	package	0603-1075	0603-1075-54	D	Discontinued by firm	2026-10-12
excluded package	package	0603-1075	0603-1075-56	D	Discontinued by firm	2026-10-12
excluded package	package	0603-1075	0603-1075-58	D	Discontinued by firm	2026-10-12

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 48 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Package NDC	Snapshot	Source SHA-256
2025-12-14 17:58 UTC · source 2025-12-05	excluded product	product		`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	0603-1075-58	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	0603-1075-56	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	0603-1075-54	`d630ba8d3edf…`	`732f749b63fb…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded product	product		`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	0603-1075-58	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	0603-1075-56	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	0603-1075-54	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded product	product		`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	0603-1075-58	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	0603-1075-56	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	0603-1075-54	`2ef7874e63bc…`	`57b86245f4fa…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded product	product		`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	0603-1075-58	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	0603-1075-56	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	0603-1075-54	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded product	product		`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	0603-1075-58	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	0603-1075-56	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	0603-1075-54	`cfe11265f3b6…`	`090c488252e2…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded product	product		`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	0603-1075-58	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	0603-1075-56	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	0603-1075-54	`cdf11ea48f46…`	`ba0047e9e063…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded product	product		`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	0603-1075-58	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	0603-1075-56	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	0603-1075-54	`302b2466d912…`	`e7b80fea0513…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded product	product		`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	0603-1075-58	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	0603-1075-56	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	0603-1075-54	`ed331223b511…`	`672a5bd82f5f…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded product	product		`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	0603-1075-58	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	0603-1075-56	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	0603-1075-54	`0efc9e666f02…`	`f202fb6c5f17…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded product	product		`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	0603-1075-58	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	0603-1075-56	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	0603-1075-54	`ad56d346431e…`	`cc804d4bbf1e…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded product	product		`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	0603-1075-58	`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	0603-1075-56	`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	0603-1075-54	`367a005e9d99…`	`383a685ebd0f…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded product	product		`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	0603-1075-58	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	0603-1075-56	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	0603-1075-54	`557ba5c1ecfa…`	`9c80585c8c6e…`

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
41b814f3-0166-1c53-c9ef-a0794c7daf9d	Product name	3	20221110
a590be26-846c-8659-a5a1-fb25907965dc	Product name	2	20221110
09d8330d-4fec-be98-3a66-f985140646b2	Product name	2	20210513
20c8cafe-5cfc-44f8-a9be-a664f437f780	Product name	2	20200225
182f9ab4-4ab5-c449-200f-87ce2ce8e550	Product name	2	20151105
e0b6c8be-f2bd-9f86-a9fc-3ed56ffaa814	Product name	3	20150910
c6fba691-a132-4ede-95c6-f8c6bd696636	Product name	1	20150902
c0200ab5-4954-454e-9676-30b741b245bd	Product name	1	20150730
4fe95224-f543-4dbb-9445-8cca122b48c8	Product name	1	20150609
e8718272-64cb-4436-969b-176c3067c8f4	Product name	1	20150609
106ff02a-57e1-4c4c-a307-fd582ff4e311	Product name	1	20150212
e9576821-a971-5261-628e-82ad9e10acdb	Product name	2	20150121
2a21311a-89e2-0e83-2ebd-117f9798b2b2	Product name	1	20140508
30c51294-7ae9-8007-7de6-58222684a0be	Product name	1	20140508
47fd879b-91c5-e1e5-130f-29d082a871ec	Product name	1	20140508
c35d1ac8-8885-2ee1-6c52-5a715b242c00	Product name	1	20140508
ce055423-1d7f-3c41-dff1-83660fa8cd96	Product name	1	20140508

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
0603-1075-54	ML - Milliliter	0603-1075	c60a8c2e-2409-4881-84bf-5ea7a871513e	1	2012-07-24
0603-1075-56	ML - Milliliter	0603-1075	38955374-289d-4a63-b987-af3b0941c044	1	2012-07-24
0603-1075-58	ML - Milliliter	0603-1075	cdb653c5-5c9e-4827-8d8b-f82b44b8371f	1	2012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
CODEINE PHOSPHATE	ACTIVE INGREDIENT	GSL05Y1MN6	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [QUALITEST PHARMACEUTICALS]	5
GUAIFENESIN	ACTIVE INGREDIENT	495W7451VQ	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [QUALITEST PHARMACEUTICALS]	5
CODEINE ANHYDROUS	ACTIVE MOIETY	UX6OWY2V7J	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [QUALITEST PHARMACEUTICALS]	5
GUAIFENESIN	ACTIVE MOIETY	495W7451VQ	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [QUALITEST PHARMACEUTICALS]	5
ALCOHOL	INACTIVE INGREDIENT	3K9958V90M	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [QUALITEST PHARMACEUTICALS]	5
ANHYDROUS CITRIC ACID	INACTIVE INGREDIENT	XF417D3PSL	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [QUALITEST PHARMACEUTICALS]	5
CARAMEL	INACTIVE INGREDIENT	T9D99G2B1R	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [QUALITEST PHARMACEUTICALS]	5
FD&C RED NO. 40	INACTIVE INGREDIENT	WZB9127XOA	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [QUALITEST PHARMACEUTICALS]	5
GLYCERIN	INACTIVE INGREDIENT	PDC6A3C0OX	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [QUALITEST PHARMACEUTICALS]	5
MENTHOL, UNSPECIFIED FORM	INACTIVE INGREDIENT	L7T10EIP3A	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [QUALITEST PHARMACEUTICALS]	5
SACCHARIN SODIUM	INACTIVE INGREDIENT	SB8ZUX40TY	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [QUALITEST PHARMACEUTICALS]	5
SODIUM BENZOATE	INACTIVE INGREDIENT	OJ245FE5EU	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [QUALITEST PHARMACEUTICALS]	5
SORBITOL	INACTIVE INGREDIENT	506T60A25R	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [QUALITEST PHARMACEUTICALS]	5
WATER	INACTIVE INGREDIENT	059QF0KO0R	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [QUALITEST PHARMACEUTICALS]	5
CODEINE PHOSPHATE	ACTIVE INGREDIENT	GSL05Y1MN6	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [DISPENSING SOLUTIONS, INC.]	2
CODEINE PHOSPHATE	ACTIVE INGREDIENT	GSL05Y1MN6	GUAIFENESIN AND CODEINE PHOSPHATE SF (GUAIFENESIN AND CODEINE PHOSPHATE) LIQUID [PHYSICIANS TOTAL CARE, INC.]	2
GUAIFENESIN	ACTIVE INGREDIENT	495W7451VQ	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [DISPENSING SOLUTIONS, INC.]	2
GUAIFENESIN	ACTIVE INGREDIENT	495W7451VQ	GUAIFENESIN AND CODEINE PHOSPHATE SF (GUAIFENESIN AND CODEINE PHOSPHATE) LIQUID [PHYSICIANS TOTAL CARE, INC.]	2
CODEINE	ACTIVE MOIETY	Q830PW7520	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [DISPENSING SOLUTIONS, INC.]	2
CODEINE	ACTIVE MOIETY	Q830PW7520	GUAIFENESIN AND CODEINE PHOSPHATE SF (GUAIFENESIN AND CODEINE PHOSPHATE) LIQUID [PHYSICIANS TOTAL CARE, INC.]	2
GUAIFENESIN	ACTIVE MOIETY	495W7451VQ	GUAIFENESIN AND CODEINE PHOSPHATE SF (GUAIFENESIN AND CODEINE PHOSPHATE) LIQUID [PHYSICIANS TOTAL CARE, INC.]	2
GUAIFENESIN	ACTIVE MOIETY	495W7451VQ	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [DISPENSING SOLUTIONS, INC.]	2
ALCOHOL	INACTIVE INGREDIENT	3K9958V90M	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [DISPENSING SOLUTIONS, INC.]	2
ALCOHOL	INACTIVE INGREDIENT	3K9958V90M	GUAIFENESIN AND CODEINE PHOSPHATE SF (GUAIFENESIN AND CODEINE PHOSPHATE) LIQUID [PHYSICIANS TOTAL CARE, INC.]	2
CARAMEL	INACTIVE INGREDIENT	T9D99G2B1R	GUAIFENESIN AND CODEINE PHOSPHATE SF (GUAIFENESIN AND CODEINE PHOSPHATE) LIQUID [PHYSICIANS TOTAL CARE, INC.]	2
CARAMEL	INACTIVE INGREDIENT	T9D99G2B1R	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [DISPENSING SOLUTIONS, INC.]	2
CITRIC ACID MONOHYDRATE	INACTIVE INGREDIENT	2968PHW8QP	GUAIFENESIN AND CODEINE PHOSPHATE SF (GUAIFENESIN AND CODEINE PHOSPHATE) LIQUID [PHYSICIANS TOTAL CARE, INC.]	2
CITRIC ACID MONOHYDRATE	INACTIVE INGREDIENT	2968PHW8QP	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [DISPENSING SOLUTIONS, INC.]	2
FD&C RED NO. 40	INACTIVE INGREDIENT	WZB9127XOA	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [DISPENSING SOLUTIONS, INC.]	2
FD&C RED NO. 40	INACTIVE INGREDIENT	WZB9127XOA	GUAIFENESIN AND CODEINE PHOSPHATE SF (GUAIFENESIN AND CODEINE PHOSPHATE) LIQUID [PHYSICIANS TOTAL CARE, INC.]	2
GLYCERIN	INACTIVE INGREDIENT	PDC6A3C0OX	GUAIFENESIN AND CODEINE PHOSPHATE SF (GUAIFENESIN AND CODEINE PHOSPHATE) LIQUID [PHYSICIANS TOTAL CARE, INC.]	2
GLYCERIN	INACTIVE INGREDIENT	PDC6A3C0OX	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [DISPENSING SOLUTIONS, INC.]	2
MENTHOL	INACTIVE INGREDIENT	L7T10EIP3A	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [DISPENSING SOLUTIONS, INC.]	2
MENTHOL	INACTIVE INGREDIENT	L7T10EIP3A	GUAIFENESIN AND CODEINE PHOSPHATE SF (GUAIFENESIN AND CODEINE PHOSPHATE) LIQUID [PHYSICIANS TOTAL CARE, INC.]	2
SACCHARIN SODIUM	INACTIVE INGREDIENT	SB8ZUX40TY	GUAIFENESIN AND CODEINE PHOSPHATE SF (GUAIFENESIN AND CODEINE PHOSPHATE) LIQUID [PHYSICIANS TOTAL CARE, INC.]	2
SACCHARIN SODIUM	INACTIVE INGREDIENT	SB8ZUX40TY	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [DISPENSING SOLUTIONS, INC.]	2
SODIUM BENZOATE	INACTIVE INGREDIENT	OJ245FE5EU	GUAIFENESIN AND CODEINE PHOSPHATE SF (GUAIFENESIN AND CODEINE PHOSPHATE) LIQUID [PHYSICIANS TOTAL CARE, INC.]	2
SODIUM BENZOATE	INACTIVE INGREDIENT	OJ245FE5EU	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [DISPENSING SOLUTIONS, INC.]	2
SORBITOL	INACTIVE INGREDIENT	506T60A25R	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [DISPENSING SOLUTIONS, INC.]	2
SORBITOL	INACTIVE INGREDIENT	506T60A25R	GUAIFENESIN AND CODEINE PHOSPHATE SF (GUAIFENESIN AND CODEINE PHOSPHATE) LIQUID [PHYSICIANS TOTAL CARE, INC.]	2
WATER	INACTIVE INGREDIENT	059QF0KO0R	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [DISPENSING SOLUTIONS, INC.]	2
WATER	INACTIVE INGREDIENT	059QF0KO0R	GUAIFENESIN AND CODEINE PHOSPHATE SF (GUAIFENESIN AND CODEINE PHOSPHATE) LIQUID [PHYSICIANS TOTAL CARE, INC.]	2
CODEINE PHOSPHATE	ACTIVE INGREDIENT	GSL05Y1MN6	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [A-S MEDICATION SOLUTIONS LLC]	1
CODEINE PHOSPHATE	ACTIVE INGREDIENT	GSL05Y1MN6	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [REBEL DISTRIBUTORS CORP]	1
GUAIFENESIN	ACTIVE INGREDIENT	495W7451VQ	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [REBEL DISTRIBUTORS CORP]	1
GUAIFENESIN	ACTIVE INGREDIENT	495W7451VQ	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [A-S MEDICATION SOLUTIONS LLC]	1
CODEINE	ACTIVE MOIETY	Q830PW7520	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [REBEL DISTRIBUTORS CORP]	1
CODEINE ANHYDROUS	ACTIVE MOIETY	UX6OWY2V7J	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [A-S MEDICATION SOLUTIONS LLC]	1
GUAIFENESIN	ACTIVE MOIETY	495W7451VQ	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [A-S MEDICATION SOLUTIONS LLC]	1
GUAIFENESIN	ACTIVE MOIETY	495W7451VQ	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [REBEL DISTRIBUTORS CORP]	1
ALCOHOL	INACTIVE INGREDIENT	3K9958V90M	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [A-S MEDICATION SOLUTIONS LLC]	1
ALCOHOL	INACTIVE INGREDIENT	3K9958V90M	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [REBEL DISTRIBUTORS CORP]	1
ANHYDROUS CITRIC ACID	INACTIVE INGREDIENT	XF417D3PSL	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [A-S MEDICATION SOLUTIONS LLC]	1
CARAMEL	INACTIVE INGREDIENT	T9D99G2B1R	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [A-S MEDICATION SOLUTIONS LLC]	1
CARAMEL	INACTIVE INGREDIENT	T9D99G2B1R	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [REBEL DISTRIBUTORS CORP]	1
CITRIC ACID	INACTIVE INGREDIENT	2968PHW8QP	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [REBEL DISTRIBUTORS CORP]	1
FD&C RED NO. 40	INACTIVE INGREDIENT	WZB9127XOA	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [REBEL DISTRIBUTORS CORP]	1
FD&C RED NO. 40	INACTIVE INGREDIENT	WZB9127XOA	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [A-S MEDICATION SOLUTIONS LLC]	1
GLYCERIN	INACTIVE INGREDIENT	PDC6A3C0OX	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [REBEL DISTRIBUTORS CORP]	1
GLYCERIN	INACTIVE INGREDIENT	PDC6A3C0OX	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [A-S MEDICATION SOLUTIONS LLC]	1
MENTHOL	INACTIVE INGREDIENT	L7T10EIP3A	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [REBEL DISTRIBUTORS CORP]	1
MENTHOL	INACTIVE INGREDIENT	L7T10EIP3A	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [A-S MEDICATION SOLUTIONS LLC]	1
SACCHARIN SODIUM	INACTIVE INGREDIENT	SB8ZUX40TY	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [REBEL DISTRIBUTORS CORP]	1
SACCHARIN SODIUM	INACTIVE INGREDIENT	SB8ZUX40TY	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [A-S MEDICATION SOLUTIONS LLC]	1
SODIUM BENZOATE	INACTIVE INGREDIENT	OJ245FE5EU	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [REBEL DISTRIBUTORS CORP]	1
SODIUM BENZOATE	INACTIVE INGREDIENT	OJ245FE5EU	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [A-S MEDICATION SOLUTIONS LLC]	1
SORBITOL	INACTIVE INGREDIENT	506T60A25R	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [REBEL DISTRIBUTORS CORP]	1
SORBITOL	INACTIVE INGREDIENT	506T60A25R	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [A-S MEDICATION SOLUTIONS LLC]	1
WATER	INACTIVE INGREDIENT	059QF0KO0R	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [A-S MEDICATION SOLUTIONS LLC]	1
WATER	INACTIVE INGREDIENT	059QF0KO0R	CHERATUSSIN AC (CODEINE PHOSPHATE AND GUAIFENESIN) LIQUID [REBEL DISTRIBUTORS CORP]	1

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
GSL05Y1MN6	CODEINE PHOSPHATE	41444-62-6	CODEINE PHOSPHATE
495W7451VQ	GUAIFENESIN	93-14-1	GUAIFENESIN

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	DailyMed	SPL version
995872	Cheratussin AC 10 MG / 100 MG in 5 mL Oral Solution	PSN	4c76c664-a999-4b6a-b4e2-5634e8539639	10
995868	codeine phosphate 10 MG / guaiFENesin 100 MG in 5 mL Oral Solution	PSN	4c76c664-a999-4b6a-b4e2-5634e8539639	10
995872	codeine phosphate 2 MG/ML / guaifenesin 20 MG/ML Oral Solution [Cheratussin]	SBD	4c76c664-a999-4b6a-b4e2-5634e8539639	10
995868	codeine phosphate 2 MG/ML / guaifenesin 20 MG/ML Oral Solution	SCD	4c76c664-a999-4b6a-b4e2-5634e8539639	10
995872	Cheratussin AC (codeine phosphate 10 MG / guaifenesin 100 MG) per 5 ML Oral Solution	SY	4c76c664-a999-4b6a-b4e2-5634e8539639	10
995868	codeine phosphate 10 MG / guaifenesin 100 MG per 5 ML Oral Solution	SY	4c76c664-a999-4b6a-b4e2-5634e8539639	10
995872	Cheratussin AC 10 MG / 100 MG in 5 mL Oral Solution	PSN	3c1b7544-cc9e-43a4-ab3a-dd410af6cd56	2
995868	codeine phosphate 10 MG / guaiFENesin 100 MG in 5 mL Oral Solution	PSN	3c1b7544-cc9e-43a4-ab3a-dd410af6cd56	2
995868	codeine phosphate 10 MG / guaiFENesin 100 MG in 5 mL Oral Solution	PSN	5b426e6a-b892-4ed9-afee-06d5a8af6320	2
995872	codeine phosphate 2 MG/ML / guaifenesin 20 MG/ML Oral Solution [Cheratussin]	SBD	3c1b7544-cc9e-43a4-ab3a-dd410af6cd56	2
995868	codeine phosphate 2 MG/ML / guaifenesin 20 MG/ML Oral Solution	SCD	3c1b7544-cc9e-43a4-ab3a-dd410af6cd56	2
995868	codeine phosphate 2 MG/ML / guaifenesin 20 MG/ML Oral Solution	SCD	5b426e6a-b892-4ed9-afee-06d5a8af6320	2
995872	Cheratussin AC (codeine phosphate 10 MG / guaifenesin 100 MG) per 5 ML Oral Solution	SY	3c1b7544-cc9e-43a4-ab3a-dd410af6cd56	2
995868	codeine phosphate 10 MG / guaifenesin 100 MG per 5 ML Oral Solution	SY	3c1b7544-cc9e-43a4-ab3a-dd410af6cd56	2
995868	codeine phosphate 10 MG / guaifenesin 100 MG per 5 ML Oral Solution	SY	5b426e6a-b892-4ed9-afee-06d5a8af6320	2

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
Cheratussin AC CV	RPK Pharmaceuticals, Inc.	2020-12-16	HUMAN OTC DRUG LABEL	3
Cheratussin® AC CV	REMEDYREPACK INC.	2019-02-04	HUMAN OTC DRUG LABEL	1
Cheratussin AC - A-S Medication Solutions	A-S Medication Solutions	2019-01-24	HUMAN OTC DRUG LABEL	10
Cheratussin® AC CV	Par Pharmaceutical	2018-12-03	HUMAN OTC DRUG LABEL	7
Cheratussin AC CV	Dispensing Solutions, Inc. \| PSS World Medical, Inc.	2012-02-15	HUMAN OTC DRUG LABEL	2
Cheratussin AC CV	Physicians Total Care, Inc.	2012-02-13	HUMAN OTC DRUG LABEL	2
Cheratussin AC CV	Rebel Distributors Corp	2011-02-09	HUMAN OTC DRUG LABEL	1